Uncategorized
FDA gives orphan drug designation to MANF for retinal artery occlusion
The FDA granted orphan drug designation to Amarantus BioScience Holdings for its investigational retinal artery occlusion treatment drug MANF, according to a press release.Mesencephalic-astrocyte-derived neurotrophic factor (MANF) is a natural protein that prevents apoptosis in response to disease or injury. The protective effects were demonstrated in animal models of retinal artery occlusion (RAO), and toxicology studies demonstrated that single intravitreal doses were well-tolerated, according to the press release.